<DOC>
	<DOCNO>NCT02642003</DOCNO>
	<brief_summary>Background Aims : Liver transplantation curative treatment modality decompensated cirrhosis limit donor organ availability financial resource ; thus many patient die await liver transplant . Granulocyte colony stimulate factor ( GCSF ) therapy mobilize bone marrow stem cell tissue regeneration , show benefit patient liver disease . The investigator evaluate efficacy GCSF therapy decompensated cirrhosis open label randomize control trial . Patients Methods : Consecutive patient decompensated cirrhosis mixed etiology randomize receive either 5-day course GCSF ( 5 μg/kg/d ) plus standard medical therapy 6 month ( Group-A ) ; standard medical therapy alone 6 month ( Group-B ) . At end 6 month survival compare .</brief_summary>
	<brief_title>To Assess Efficacy Granulocyte Colony Stimulating Factor Versus Standard Medical Therapy Patients Decompensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age 18 year to75 year Patients decompensated cirrhosis CTP ≥6 ≤ 13 Liver transplantation feasible soon ( due financial reason unavailability donor ) . Hepatocellular Carcinoma Sepsis ( Any culture positive : blood , urine , obvious source infection : UTI , SBP ) : Patients include sepsis control . Any organ failure Grade 3 4 Hepatic Encephalopathy , Active Variceal bleed , Hepatorenal Syndrome : Patients might include clinical improvement HIV seropositivity Pregnancy Refusal participate study Previous know hypersensitivity GCSF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>